hypoparathyroidism

Septerna files for IPO on strength of preclinical data, vision for expanding GPCR landscape
Fierce Biotech
Thu, 10/3/24 - 10:32 am
Septerna
IPOs
hypoparathyroidism
A First for Hypoparathyroidism — Yorvipath (Palopegteriparatide) Earns FDA Nod
Xtalks
Thu, 08/22/24 - 09:51 pm
Yorvipath
FDA
hypoparathyroidism
Ascendis Pharma
Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath
Fierce Pharma
Mon, 08/12/24 - 11:35 am
Ascendis Pharma
hypoparathyroidism
FDA
Yorvipath
Another delay for Ascendis' hormone therapy as FDA extends review by 3 months
Fierce Pharma
Tue, 05/14/24 - 11:06 pm
Ascendis Pharma
Transcon PTH
FDA
hypoparathyroidism
AstraZeneca boosts rare disease portfolio with $1.05B Amolyt acquisition
BioSpace
Thu, 03/14/24 - 11:38 am
AstraZeneca
M&A
Amolyt Pharma
eneboparatide
hypoparathyroidism
FDA cites ‘deficiencies’ in Ascendis’ application for parathyroid drug, jeopardizing potential approval
Endpoints
Tue, 04/4/23 - 12:32 pm
Ascendis Pharma
hypoparathyroidism
FDA
Takeda to stop making parathyroid drug Natpara in 2024 after production challenges
BioPharma Dive
Tue, 10/4/22 - 11:40 pm
Takeda
Natpara
drug manufacturing
hypoparathyroidism
Return of Takeda’s Parathyroid Hormone Injection Delayed Indefinitely
BioSpace
Tue, 03/22/22 - 11:16 pm
Takeda
parathyroid
hypoparathyroidism
Natpara
FDA
2,400 people remain without rare disease drug as Takeda manufacturing woes continue
Endpoints
Mon, 04/5/21 - 02:55 pm
Takeda
hypoparathyroidism
drug manufacturing
Natpara
With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug
Fierce Biotech
Mon, 03/22/21 - 10:31 am
BridgeBio
hypoparathyroidism
clinical trials
encaleret
The window of opportunity opens wider for Ascendis
EP Vantage
Tue, 09/29/20 - 11:53 am
Ascendis Pharma
Transcon PTH
hypoparathyroidism
Orphan Drug Recall Leaves Patients in the Lurch
RAPS.org
Mon, 11/11/19 - 10:43 am
hypoparathyroidism
patients
product recalls
Takeda
Natpara
Lawmakers Seek Clarity From FDA on Recall of Lifesaving Drug
RAPS.org
Sat, 10/19/19 - 01:47 pm
Takeda Pharmaceuticals
hypoparathyroidism
Natpara
FDA
product recalls
Shire’s $5.2 Billion Gamble Pays Off as NPS Drug Wins Approval
Bloomberg
Sat, 01/24/15 - 09:39 am
Shire
NPS Pharmaceuticals
Natpara
hypoparathyroidism
NPS Pharma will have to wait another three months for an FDA OK
Fierce Biotech
Sat, 10/25/14 - 09:42 am
NPS Pharmaceuticals
Natpara
hypoparathyroidism
FDA
FDA staff: NPS drug effective; no significant safety imbalance
Yahoo/Reuters
Wed, 09/10/14 - 08:59 am
NPS Pharmaceuticals
FDA
Natpara
hypoparathyroidism
NPS Pharma Finds Big Success In Tiny Markets
Investors.com
Fri, 02/14/14 - 12:00 pm
NPS Pharmaceuticals
Gattex
short bowel syndrome
Natpara
hypoparathyroidism
NPS Pharmaceuticals Enrolls First Patient in Global Registry Designed to Characterize the Natural History of Hypoparathyroidism
Yahoo/BusinessWire
Thu, 08/1/13 - 08:41 am
NPS Pharmaceuticals
hypoparathyroidism
NPS wraps another positive PhIII study as parathyroid drug impresses
Fierce Biotech
Mon, 11/7/11 - 11:07 am
NPS Pharmaceuticals
hypoparathyroidism
NPSP558